# FACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast Cancer

> **NCT03944434** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Fondazione Sandro Pitigliani** · enrollment: 116 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Ribociclib
- **DRUG:** Aromatase Inhibitors, non steroideal
- **DRUG:** LHRH agonist

## Key facts

- **NCT ID:** NCT03944434
- **Lead sponsor:** Fondazione Sandro Pitigliani
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-12-27
- **Primary completion:** 2024-12-27
- **Final completion:** 2025-11-27
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2025-02-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03944434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03944434, "FACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03944434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*